363 related articles for article (PubMed ID: 26347163)
1. Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.
Tomita Y
Int J Urol; 2016 Jan; 23(1):13-21. PubMed ID: 26347163
[TBL] [Abstract][Full Text] [Related]
2. Role of targeted therapy in combination with surgery in renal cell carcinoma.
Bex A; Powles T; Karam JA
Int J Urol; 2016 Jan; 23(1):5-12. PubMed ID: 26238981
[TBL] [Abstract][Full Text] [Related]
3. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
Shuch B; Riggs SB; LaRochelle JC; Kabbinavar FF; Avakian R; Pantuck AJ; Patard JJ; Belldegrun AS
BJU Int; 2008 Sep; 102(6):692-6. PubMed ID: 18410444
[TBL] [Abstract][Full Text] [Related]
5. The role of cytoreductive surgery in the era of targeted agents.
Noe A; Stewart GD; Bex A
Curr Opin Urol; 2015 Sep; 25(5):374-80. PubMed ID: 26075568
[TBL] [Abstract][Full Text] [Related]
6. Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma.
Noronha V; Joshi A; Bakshi G; Tongaonkar H; Prabhash K
Indian J Cancer; 2016; 53(1):102-8. PubMed ID: 27146754
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.
Shinohara N; Abe T
Int J Urol; 2015 Oct; 22(10):888-97. PubMed ID: 26147084
[TBL] [Abstract][Full Text] [Related]
8. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
Kondo T; Hashimoto Y; Kobayashi H; Iizuka J; Nishikawa T; Nakano M; Tanabe K
Jpn J Clin Oncol; 2010 Dec; 40(12):1173-9. PubMed ID: 20696817
[TBL] [Abstract][Full Text] [Related]
9. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.
Silberstein JL; Millard F; Mehrazin R; Kopp R; Bazzi W; DiBlasio CJ; Patterson AL; Downs TM; Yunus F; Kane CJ; Derweesh IH
BJU Int; 2010 Nov; 106(9):1270-6. PubMed ID: 20394613
[TBL] [Abstract][Full Text] [Related]
11. Novel targeted therapy for advanced renal carcinoma: trials in progress.
Calabrò F; Sternberg CN
Curr Opin Urol; 2010 Sep; 20(5):382-7. PubMed ID: 20625300
[TBL] [Abstract][Full Text] [Related]
12. [Complete response to tyrosine kinase inhibitors in metastatic renal cancer. Report of four cases].
Soto M; Campanario R; Saiz R; Juárez A
Arch Esp Urol; 2016 Sep; 69(7):440-3. PubMed ID: 27617555
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
Bex A; Mulders P; Jewett M; Wagstaff J; van Thienen JV; Blank CU; van Velthoven R; Del Pilar Laguna M; Wood L; van Melick HHE; Aarts MJ; Lattouf JB; Powles T; de Jong Md PhD IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen J
JAMA Oncol; 2019 Feb; 5(2):164-170. PubMed ID: 30543350
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature.
Daste A; Gross-Goupil M; Quivy A; François L; Bernhard JC; Ravaud A
Clin Genitourin Cancer; 2016 Oct; 14(5):e525-e527. PubMed ID: 27185091
[No Abstract] [Full Text] [Related]
15. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of pre-surgical axitinib for shrinkage of inferior vena cava thrombus in a patient with advanced renal cell carcinoma.
Sassa N; Kato M; Funahashi Y; Maeda M; Inoue S; Gotoh M
Jpn J Clin Oncol; 2014 Apr; 44(4):370-3. PubMed ID: 24571808
[TBL] [Abstract][Full Text] [Related]
17. Axitinib for the treatment of metastatic renal cell carcinoma.
Parekh H; Griswold J; Rini B
Future Oncol; 2016 Feb; 12(3):303-11. PubMed ID: 26769075
[TBL] [Abstract][Full Text] [Related]
18. An update on targeted therapy in metastatic renal cell carcinoma.
Lombardi G; Zustovich F; Donach M; Dalla Palma M; Nicoletto O; Pastorelli D
Urol Oncol; 2012; 30(3):240-6. PubMed ID: 20456985
[TBL] [Abstract][Full Text] [Related]
19. Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift?
Dariane C; Timsit MO; Méjean A
Bull Cancer; 2018 Dec; 105 Suppl 3():S229-S234. PubMed ID: 30595151
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]